Clinical Trials
MacuCLEAR has completed a pre-Investigational New Drug (IND) meeting with the FDA. Its successful pre-clinical work and choice of lead compound has resulted in FDA granting 505 (b)2 status and Fast Track eligibility. MacuCLEAR expects to complete its IND filing by the end of the third quarter and to be in human clinicals by fourth quarter of 2008.